NCT06809569View on ClinicalTrials.gov

A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions

Healthy

Interventions

DRUG

Allyl Isothiocyanate (AITC)

Topical administration

DRUG

Capsaicin

Intradermal administration

OTHER

Vehicle for AITC

Topical administration

OTHER

Vehicle for Capsaicin

Intradermal administration

Trial Locations (1)

3000

Center for Clinical Pharmacology (CCP) (Site 0001), Leuven

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06809569 - A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420) | Biotech Hunter | Biotech Hunter